Moderna-Merck personalised vaccine cuts melanoma return risk by 42%

An experimental personalised cancer vaccine from Moderna and Merck reduced the risk of melanoma returning by 42% when added to standard treatment after surgery, the drugmakers said. Called intismeran, the vaccine is tailored to each patient's tumour and uses the same mRNA technology as Covid-19 vaccines. The findings, measuring recurrence over two years, come from the most advanced study yet of the approach.